What is A-Alpha Bio?
A-Alpha Bio operates at the vanguard of the biotechnology industry, specializing in the development of advanced computational tools that integrate seamlessly with high-throughput yeast experiments. By mapping the complex landscape of protein-protein interactions, the company provides pharmaceutical partners with actionable insights that accelerate the discovery of novel therapeutic candidates. Its market position is defined by a dual-focus on data-driven precision and biological scalability, allowing it to address some of the most persistent bottlenecks in drug development. As the industry shifts toward more predictive, AI-augmented research models, A-Alpha Bio remains a critical infrastructure provider for the next generation of life sciences innovation.
How much funding has A-Alpha Bio raised?
A-Alpha Bio has raised a total of $68.3M across 3 funding rounds:
Angel/Seed
$2.8M
Series A
$51M
Other Financing Round
$14.5M
Angel/Seed (2019): $2.8M with participation from Sahsen Ventures, biotech angel investors, OS Fund, Madrona Venture Group, AME Cloud Ventures, Washington Research Foundation, and Boom Capital
Series A (2023): $51M led by Perceptive Advisors, Perceptive Xontogeny Ventures, Madrona Venture Group, and Lux Capital
Other Financing Round (2024): $14.5M supported by U.S. Department of Defense
Key Investors in A-Alpha Bio
Perceptive Advisors
A prominent investment firm managing significant assets, specializing in the healthcare and life sciences sectors to drive innovation in medical technology.
Madrona Venture Group
A long-standing venture capital firm with a deep focus on software, services, and technology-driven enterprises, providing critical support to Pacific Northwest innovators.
Lux Capital
A venture capital firm that invests in frontier science and technology, backing companies at the intersection of biotechnology, AI, and advanced materials.
What's next for A-Alpha Bio?
With the successful closure of its latest financing round, A-Alpha Bio is well-positioned to scale its operational capacity and expand its collaborative research footprint. The strategic nature of this recent capital injection suggests a focus on deepening existing enterprise partnerships and potentially diversifying its internal pipeline of therapeutic assets. Moving forward, the company is expected to leverage its computational engine to tackle increasingly complex biological targets, further cementing its status as an essential partner for global pharmaceutical firms. The focus will likely remain on enhancing the throughput of its discovery platform while maintaining the high-fidelity data standards that have attracted significant institutional interest to date.
See full A-Alpha Bio company page
